

EXHIBIT “B”

A Passion to Perform.



Account Name: Janssen Pharmaceutica (J&J) Settlement
 Portfolio Name: PROPULSID ATTORNEYS FEE FUND
 Portfolio Number: 26620.3
 Statement Period: January 1, 2012 - January 31, 2012
 Account Administrator: ANABELLE ROA (212-250-5863)
 Account Manager: KISHA HOLDER (212-250-7863)
 Team Leader: CHRISTINA VANRYZIN (212-250-4391)

Summary

Portfolio Market Value Summary as of 01/31/12		
Cash	\$	0.00
Investments	\$	7,284,054.36
Total Portfolio Value	\$	7,284,054.36
YTD Dividends :	\$	37.51
YTD Interest :	\$	0.00
YTD Capital Gains/Losses :	\$	0.00

Portfolio Cost Value Summary as of 01/31/12		
Cash	\$	0.00
Investments	\$	7,284,054.36
Total Portfolio Value	\$	7,284,054.36

Cash Summary

Beginning Balance	\$	0.00
--------------------------	----	-------------

Disbursements:		
Dividends Reinvested	\$	37.51
Total Disbursements		
Closing Balance	\$	0.00

Case 2:00-md-01355-EEF-KWR Document 4465-3 Filed 03/15/12 Page 2 of 4



Account Name: Janssen Pharmaceutica (J&J) Settlement
 Portfolio Name: PROPULSID ATTORNEYS FEE FUND
 Portfolio Number: 26620.3
 Statement Period: January 1, 2012 - January 31, 2012
 Account Administrator: ANABELLE ROA (212-250-5863)
 Account Manager: KISHA HOLDER (212-250-7863)
 Team Leader: CHRISTINA VANRYZIN (212-250-4391)

Transaction Statement for the period of January 1, 2012 through January 31, 2012

DATE	Transaction Description	Cash	Face/Par	Cap Gain/Loss	Price	Cash Balance	Fund Balance
01/01						\$ 0.00	\$ 7,284,016.95
01/03	Dividend Reinvestment GS #489-Fin SQ Treas Obl Pref CUSIP: 38141W281 / ISIN: US38141W2818	\$ 0.00	\$ 87.51	\$ 0.00	\$ 0.00	\$ 0.00	\$ 7,284,054.36

Investment Positions as of January 31, 2012

Description	Original Units	Cost	Current Units	Market Price	Yield	Market Value	Accrued Income	Moody Rating & P Rating
GS #489-Fin SQ Treas Obl Pref CUSIP: 38141W281	7,284,054.36	\$7,284,054.36	7,284,054.36	\$1.00	0.01%	\$7,284,054.36	\$37.51	n/a / N/A
Total Portfolio	7,284,054.36	\$7,284,054.36	7,284,054.36			\$7,284,054.36	\$37.51	

A Passion to Perform.

Deutsche Bank



Account Name: Janssen Pharmaceutica (J&J) Settlement
 Portfolio Name: PROPULSID ATTORNEYS FEE FUND
 Portfolio Number: 26620.3
 Statement Period: January 1, 2012 - January 31, 2012
 Account Administrator: ANABELLE ROA (212-250-5863)
 Account Manager: KISHA HOLDER (212-250-7863)
 Team Leader: CHRISTINA VANRYZIN (212-250-4391)

Disclosure Notice:

Certain investments made for the Account(s) shown above may have been executed through Deutsche Bank Trust Company Americas (DBTCA), or an affiliate. Usual or customary charges may be included and retained by DBTCA, or an affiliate, as a part of the execution price. Trade confirmations are available upon customer request for no additional charge.

DBTCA provides a wide range of mutual fund investment options. The investment yield, fee structure, minimum investment amounts, as well as other important terms and conditions, vary from fund to fund. Please contact your Account Representative with any questions or to request a prospectus describing any of our mutual fund investment options.

If you are invested in a proprietary mutual fund, DBTCA and/or our affiliates may earn investment management fees and other fees associated with these funds, as disclosed in the relevant fund's prospectus. DBTCA has entered into agreements with certain mutual funds, including proprietary mutual funds, or their agents, to provide certain shareholder services to these funds. DBTCA is paid a fee by the mutual funds for providing these shareholder services that, calculated on an annual basis, does not exceed 80 basis points per annum of the average daily balance of the amount of your investment in these funds.

All prices stated herein, with respect to any asset, have been obtained from third party sources. Asset and Industry classification has been obtained from Bloomberg and is provided solely for informational purposes.

This statement shall be deemed correct and final unless DBTCA is notified in writing by the Addressee to the contrary, within thirty (30) business days of the date of the statement.

Case 2:00-md-01355-FCF-KWR Document 4465-3 Filed 03/15/12 Page 4 of 4

